ArticleBreast cancer research : BCR2026

Synergistic lethality of combination treatment with Trop2-directed antibody-drug conjugate sacituzumab govitecan and TRAIL agonists in triple negative breast cancer.

Yonit A Addissie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.